<DOC>
	<DOCNO>NCT02968914</DOCNO>
	<brief_summary>An open-label , single dose Pharmacokinetic ( PK ) comparability study demonstrate comparable drug exposure follow Subcutaneous benralizumab administration use accessorized pre-filled syringe ( APFS ) autoinjector ( AI ) device .</brief_summary>
	<brief_title>Pharmacokinetic Comparability Benralizumab Using Accessorized Pre-Filled Syringe Autoinjector Healthy Volunteers</brief_title>
	<detailed_description>A study descriptive comparison benralizumab PK weight injection site . This study multicenter , randomize , open-label , parallel group Phase 1 study design compare benralizumab PK exposure healthy subject follow single subcutaneous ( SC ) administration fix 30 mg dose benralizumab use APFS single-use AI . Eligible subject healthy subject age 18 55 year , body weight 55 100 kg body mass index 18 29.9 kg/m2 . A total 180 subject randomize . Randomization stratify weight group ( 55 69.9 kg , 70 84.9 kg 85 100 kg ) , within 3 weight group , subject randomize 1:1:1:1:1:1 1 6 combination treatment ( APFS AI ) injection site ( upper arm , abdomen thigh ) , present Table 1 . This study perform 2 study center .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Healthy male and/or female subject nonchildbearing potential age 18 55 year ( inclusive ) suitable vein cannulation repeat venipuncture . Females must non pregnant , non lactate nonchildbearing potential , confirm screen Sexually active male willingness use contraception Body mass index ( BMI ) 18 29.9 kg/m2 inclusive weigh least 55 kg 100 kg inclusive . History clinically significant disease , severe allergy/anaphylaxis biologic therapy , GuillainBarré syndrome , smoke alcohol drug abuse Diagnosis helminth parasitic infection acute upper low respiratory infection Disorders relate cardiovascular , gastrointestinal , hepatic , renal , neurological , musculoskeletal , infectious , endocrine , metabolic , hematological , psychiatric , major physical impairment Alanine aminotransferase/aspartate aminotransferase level ≥1.5 time upper limit normal White blood cell count neutrophil &lt; low limit normal Any clinically significant illness , medical/surgical procedure , trauma within 4 week first administration Investigational medicinal product ( IMP ) Positive result serum hepatitis B surface antigen antiHemoglobin C ( antiHBc ) antibody , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody . Intake new chemical entity ( approved marketing ) within 3 month first administration investigational product Plasma donation within 1 month screen blood donation/loss 500 mL 3 month prior screen Receipt immunoglobulin blood product within 30 day prior date informed consent Receipt market ( e.g. , omalizumab , mepolizumab etc . ) investigational biologic within 4 month 5 halflives prior date inform consent Receipt live attenuate vaccine 30 day prior randomization Day 1 Current malignancy , history malignancy except ( basal cell carcinoma , localize squamous cell carcinoma skin situ carcinoma cervix ) Use drug enzymeinducing property St John 's Wort within 3 week prior first administration IMP . Use antacid , analgesic ( except paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( 20 600 time recommended daily dose ) mineral 2 week prior first administration IMP longer Previous receipt receive benralizumab Any ongoing recent minor medical complaint Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Chronic Obstructive pulmonary Disease</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>